A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.

NCT00341055 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia
Cancer
Chemotherapy

Interventions

DRUG: Epoetin alfa

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]